nilotinib hydrochloride dihydrate

Nilotinib hydrochloride dihydrate is a small-molecule tyrosine kinase inhibitor approved for the treatment of imatinib-resistant chronic myelogenous leukemia.

Nilotinib dihydrochloride dihydrate is a small-molecule tyrosine kinase inhibitor approved for the treatment of imatinib-resistant chronic myelogenous leukemia.

Nilotinib hydrochloride(AMN-107 HCl) 是一种可口服的 Bcr-Abl 酪氨酸激酶抑制，具有抗肿瘤活性，可用于调节神经炎症和认知障碍，可用于研究慢性骨髓性白血病。

Nilotinib (AMN107) 是一种 Bcr-Abl 酪氨酸激酶抑制剂，具有口服活性。Nilotinib 具有抗肿瘤活性，可以用于治疗 Imatinib 耐药的慢性粒细胞性白血病 (CML)。

Nilotinib D6 is a deuterium labeled Nilotinib which is an orally available inhibitor of Bcr-Abl tyrosine kinase ,and with antineoplastic activity.

Nilotinib monohydrochloride monohydrate (Nilotinib (monohydrochloride monohydrate)) 是酪氨酸酶抑制剂，有效抑制 BCR-ABL 及其突变体。